Opportunity ID: 339392
General Information
Document Type: | Grants Notice |
Funding Opportunity Number: | W81XWH-22-NFRP-CTA |
Funding Opportunity Title: | DoD Neurofibromatosis, Clinical Trial Award |
Opportunity Category: | Discretionary |
Opportunity Category Explanation: | – |
Funding Instrument Type: | Cooperative Agreement Grant |
Category of Funding Activity: | Science and Technology and other Research and Development |
Category Explanation: | – |
Expected Number of Awards: | 1 |
Assistance Listings: | 12.420 — Military Medical Research and Development |
Cost Sharing or Matching Requirement: | No |
Version: | Synopsis 2 |
Posted Date: | Apr 11, 2022 |
Last Updated Date: | Apr 27, 2022 |
Original Closing Date for Applications: | Jul 21, 2022 |
Current Closing Date for Applications: | Jul 21, 2022 |
Archive Date: | Aug 20, 2022 |
Estimated Total Program Funding: | $1,600,000 |
Award Ceiling: | – |
Award Floor: | – |
Eligibility
Eligible Applicants: | Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled “Additional Information on Eligibility” |
Additional Information on Eligibility: | – |
Additional Information
Agency Name: | Dept. of the Army — USAMRAA |
Description: |
The NFRP Clinical Trial Award supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of NF. Clinical trials may be designed to evaluate promising new products, pharmacologic agents (drugs or biologics), devices, clinical guidance, and/or emerging approaches and technologies. Proposed projects may range from small proof-of-concept trials (e.g., pilot, first-in-human, phase 0) to demonstrate feasibility or inform the design of more advanced trials through large-scale trials to determine efficacy in relevant patient populations. Funding from this award mechanism must support a clinical trial. A clinical trial is defined as a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include placebo or other control) to evaluate the effects of the interventions on biomedical or behavioral health-related outcomes. For more information, a Human Research Protections Office Resources and Overview document is provided at https://cdmrp.army.mil/pubs/pdf/Human%20Subjects%20Resource%20Document.pdf. Principal Investigators (PIs) seeking funding for a preclinical research project should consider one of the other FY22 NFRP program announcements being offered. |
Link to Additional Information: | – |
Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
CDMRP Help Desk
Phone: 301-682-5507 Email: help@eBRAP.org Email:help@eBRAP.org |
Version History
Version | Modification Description | Updated Date |
---|---|---|
The funding opportunity modification includes an update to the delegated authority provided by United States Code, Title 10, Section 2358 to the current version is "United States Code, Title 10, Section 4001 (10 USC 4001). The revised program announcement also includes a correction to the "Statistical Plan and Data Analysis" Peer Review evaluation criteria. | Apr 27, 2022 | |
Apr 11, 2022 |
DISPLAYING: Synopsis 2
General Information
Document Type: | Grants Notice |
Funding Opportunity Number: | W81XWH-22-NFRP-CTA |
Funding Opportunity Title: | DoD Neurofibromatosis, Clinical Trial Award |
Opportunity Category: | Discretionary |
Opportunity Category Explanation: | – |
Funding Instrument Type: | Cooperative Agreement Grant |
Category of Funding Activity: | Science and Technology and other Research and Development |
Category Explanation: | – |
Expected Number of Awards: | 1 |
Assistance Listings: | 12.420 — Military Medical Research and Development |
Cost Sharing or Matching Requirement: | No |
Version: | Synopsis 2 |
Posted Date: | Apr 11, 2022 |
Last Updated Date: | Apr 27, 2022 |
Original Closing Date for Applications: | Jul 21, 2022 |
Current Closing Date for Applications: | Jul 21, 2022 |
Archive Date: | Aug 20, 2022 |
Estimated Total Program Funding: | $1,600,000 |
Award Ceiling: | – |
Award Floor: | – |
Eligibility
Eligible Applicants: | Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled “Additional Information on Eligibility” |
Additional Information on Eligibility: | – |
Additional Information
Agency Name: | Dept. of the Army — USAMRAA |
Description: |
The NFRP Clinical Trial Award supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of NF. Clinical trials may be designed to evaluate promising new products, pharmacologic agents (drugs or biologics), devices, clinical guidance, and/or emerging approaches and technologies. Proposed projects may range from small proof-of-concept trials (e.g., pilot, first-in-human, phase 0) to demonstrate feasibility or inform the design of more advanced trials through large-scale trials to determine efficacy in relevant patient populations. Funding from this award mechanism must support a clinical trial. A clinical trial is defined as a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include placebo or other control) to evaluate the effects of the interventions on biomedical or behavioral health-related outcomes. For more information, a Human Research Protections Office Resources and Overview document is provided at https://cdmrp.army.mil/pubs/pdf/Human%20Subjects%20Resource%20Document.pdf. Principal Investigators (PIs) seeking funding for a preclinical research project should consider one of the other FY22 NFRP program announcements being offered. |
Link to Additional Information: | – |
Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
CDMRP Help Desk
Phone: 301-682-5507 Email: help@eBRAP.org Email:help@eBRAP.org |
DISPLAYING: Synopsis 1
General Information
Document Type: | Grants Notice |
Funding Opportunity Number: | W81XWH-22-NFRP-CTA |
Funding Opportunity Title: | DoD Neurofibromatosis, Clinical Trial Award |
Opportunity Category: | Discretionary |
Opportunity Category Explanation: | – |
Funding Instrument Type: | Cooperative Agreement Grant |
Category of Funding Activity: | Science and Technology and other Research and Development |
Category Explanation: | – |
Expected Number of Awards: | 1 |
Assistance Listings: | 12.420 — Military Medical Research and Development |
Cost Sharing or Matching Requirement: | No |
Version: | Synopsis 1 |
Posted Date: | Apr 11, 2022 |
Last Updated Date: | Apr 11, 2022 |
Original Closing Date for Applications: | – |
Current Closing Date for Applications: | Jul 21, 2022 |
Archive Date: | Aug 20, 2022 |
Estimated Total Program Funding: | $1,600,000 |
Award Ceiling: | – |
Award Floor: | – |
Eligibility
Eligible Applicants: | Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled “Additional Information on Eligibility” |
Additional Information on Eligibility: | – |
Additional Information
Agency Name: | Dept. of the Army — USAMRAA |
Description: |
The NFRP Clinical Trial Award supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of NF. Clinical trials may be designed to evaluate promising new products, pharmacologic agents (drugs or biologics), devices, clinical guidance, and/or emerging approaches and technologies. Proposed projects may range from small proof-of-concept trials (e.g., pilot, first-in-human, phase 0) to demonstrate feasibility or inform the design of more advanced trials through large-scale trials to determine efficacy in relevant patient populations. Funding from this award mechanism must support a clinical trial. A clinical trial is defined as a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include placebo or other control) to evaluate the effects of the interventions on biomedical or behavioral health-related outcomes. For more information, a Human Research Protections Office Resources and Overview document is provided at https://cdmrp.army.mil/pubs/pdf/Human%20Subjects%20Resource%20Document.pdf. Principal Investigators (PIs) seeking funding for a preclinical research project should consider one of the other FY22 NFRP program announcements being offered. |
Link to Additional Information: | – |
Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
CDMRP Help Desk
Phone: 301-682-5507 Email: help@eBRAP.org Email:help@eBRAP.org |
Related Documents
Packages
Agency Contact Information: | CDMRP Help Desk Phone: 301-682-5507 Email: help@eBRAP.org Email: help@eBRAP.org |
Who Can Apply: | Organization Applicants |
Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
---|---|---|---|---|---|---|
12.420 | PKG00273244 | Apr 11, 2022 | Jul 21, 2022 | View |